Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: Significant bone health issues in those not taking HRT

British Journal of Cancer

Volumn 105, Issue 1, 2011, Pages 22-27

  Challberg, J ^a   Ashcroft, L ^a   Lalloo, F ^a   Eckersley, B ^b   Clayton, R ^a   Hopwood, P ^c   Selby, P ^a   Howell, A ^a,b   Evans, D G ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

breast cancer; HRT; menopause; oophorectomy; osteopenia; osteoporosis

Indexed keywords

ESTROGEN;

ADULT; ARTICLE; BONE DENSITY; BONE EXAMINATION; CANCER RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; ENDOCRINE DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OVARY CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; RISK; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HEALTH STATUS; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTORS; SALPINGOSTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959708888     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.202     Document Type: Article

References (34)

1. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. J Am Med Assoc 290(13): 1739-1748 (Pubitemid 37430624)
2. Antoniou A, Pharoah PP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5): 1117-1130 (Pubitemid 36530000)
3. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004) Hormone replacement therapy and life expectancy after prophylactic oophorect-omy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22(6): 1045-1054 (Pubitemid 41095037)
4. Beral V, Reeves G, Bull D, Green J, Million Women Study Collaborators (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4): 296-305
5. Cann C, Gordon H, Ettinger B, Gordon G (1980) Spinal mineral loss in oophorectomized women. Determination by quantitative computed tomography. J Am Med Assoc 244: 2056-2059 (Pubitemid 10024422)
6. Collaborators MWS (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427
7. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339(11): 733-738 (Pubitemid 28417356)
8. Elit L, Esplen MJ, Butler K, Narod S (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1: 149-156
9. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A (2009a) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9): 593-597
10. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A (2009b) Uptake of risk reducing surgery in unaffected women at high risk of breast cancer and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 18(8): 2318-2324
11. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1): 155
12. Ewertz M, Mellemkjaer L, Poulen AH, Friis S, Sørensen HT, Pedersen L, McLaughlin JK, Olsen JH (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92: 1293-1297 (Pubitemid 40604407)
13. Fallowfield LJ, Leaity S, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine subscale for the FACT-B. Breast Cancer Res Treat 55: 189-199 (Pubitemid 29389581)
14. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA (2006) Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 85(5): 1432-1440
15. Hermsen BB, Olivier RI, Verheigen RHM, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA (2007) No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 96: 1335-1342 (Pubitemid 46685786)
16. Howell A, Evans DG (2011) Hormone replacement therapy and breast cancer. Recent Results Cancer Res 188: 115-122
17. Jones KP, Ravniker VA, Tulchinsky D, Schiff I (1985) Comparison of bone density in amenorrheic women due to athletics, weight loss, and premature menopause. Obstet Gynecol 66(1): 5-8 (Pubitemid 15047373)
18. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305(13): 1305-1314
19. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28): 6890-6898
20. Morrison PJ, Hodgson S, Haites NE (2002) Familial Breast and Ovarian Cancer. Cambridge University Press: Cambridge
21. Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA (2006) Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94: 814-819
22. Risch HA, McLaughlin J, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68: 700-710 (Pubitemid 32203724)
23. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL, PROSE Study Group (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23: 7804-7810 (Pubitemid 46657377)
24. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21): 1616-1622 (Pubitemid 34755669)
25. Rivera CM, Grossardt BR, Rhodes DJ, Rocca WA (2009) Increased cardiovascular mortality after bilateral oophorectomy. Menopause 16: 15-23
26. Rocca WA, Shuster LT, Grossardt BR, Maraganore DM, Gostout BS, Geda YE, Melton III LJ (2009) Long-term effects of bilateral oophor-ectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) 5(1): 39-48
27. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE (2009) Bayesian meta-analysis of hormone therapy and mortality in younger postmeno-pausal women. Am J Med 122(11): 1016-1022.e1
28. Schildkraut J, Thompson WD (1988) Familial ovarian cancer: a population based case-control study. Am J Epidemiol 128: 456-466
29. Teneriello MG, Park RC (1995) The early detection of ovarian cancer. CA Cancer J Clin 45: 71-87
30. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA (2010) Premature menopause or early menopause: long-term health consequences. Maturitas 65(2): 161-166
31. Tham YL, Sexton K, Weiss HL, Elledge RM, Friedman LC, Kramer RM (2006) The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J Support Oncol 4(6): 295-298, 304 (Pubitemid 44203633)
32. van der Voort DJ, van Der Weiger PH, Barentsen R (2003) Early menopause: increased fracture risk at older age. Osteoporos Int 14(6): 525-530 (Pubitemid 36919215)
33. Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504 (Pubitemid 27097597)
34. WHO (1994) Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. World Health Organ Tech Rep Ser 843: 1-129.